Medical devices to treat or inhibit restenosis
First Claim
1. An implantable medical device for the treatment or inhibition of restenosis coated with an endothelin receptor inhibitor selected from the group consisting of atrasentan, and pharmaceutically acceptable derivatives thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain endothelin receptor inhibitor, are disclosed. The anti-restenotic endothelin receptor inhibitor is atrasentan, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the endothelin receptor inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-endothelin receptor inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one endothelin receptor inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.
-
Citations
14 Claims
- 1. An implantable medical device for the treatment or inhibition of restenosis coated with an endothelin receptor inhibitor selected from the group consisting of atrasentan, and pharmaceutically acceptable derivatives thereof.
- 5. An intravascular stent for site-specific, controlled-release delivery of a medicament for the treatment or inhibition of restenosis, said stent having a coating comprising a biocompatible polymer and an endothelin receptor inhibitor selected from the group consisting of atrasentan and pharmaceutically acceptable derivatives thereof.
-
9. A method of treating or inhibiting restenosis comprising:
-
providing an intravascular stent having a coating comprising an endothelin receptor inhibitor selected from the group consisting of atrasentan and pharmaceutically acceptable derivatives thereof; and
implanting said intravascular stent into a blood vessel lumen at risk for restenosis wherein said endothelin receptor inhibitor is released into tissue adjacent said blood vessel lumen in a controlled release manner. - View Dependent Claims (10)
-
-
11. A method for producing a medical device comprising:
-
providing medical device to be coated;
compounding atrasentan or a pharmaceutically acceptable derivative thereof with a carrier compound; and
coating said medical device with said atrasentan or pharmaceutically acceptable derivative thereof compounded with said carrier compound. - View Dependent Claims (12, 13, 14)
-
Specification